At a glance
ClinicalIndex Comparison Record- ✓Age 18 years or older
- ✓Life expectancy greater than 10 years
- ✓WHO performance status 0-1
- ✓Histologically confirmed prostate cancer in prostatectomy specimen
- ✕Metastases (regional lymph nodes or distant) on imaging
- ✕Prior or ongoing hormonal therapy (antiandrogens or GnRH)
- ✕Prior pelvic radiotherapy
- ✕Prior malignancy other than prostate cancer and basalioma in past 5 years
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Personalized Radiotherapy for Biochemical Recurrence of Prostate Cancer After Prostatectomy: a Randomized Phase III Study.
In Brief
A clinical study evaluating Radiation to the prostate bed with or without addition of radiation of lymph node irradiation. for Prostate Cancer. Currently recruiting, targeting 374 participants across 3 sites.
Signals
Detailed Summary
A randomized phase III trial to study the effect of adding lymph node irradiation in patients with poor prostate-specific antigen (PSA) response during salvage radiotherapy for biochemical recurrence (0.15 ≤ PSA \<0.70 ng/ml) after prostatectomy.
Study Details
Timeline
Interventions
Radiation to the prostate bed with or without addition of radiation of lymph node irradiation (non responders). Patients with PSA response continues radiotherapy as initially planned, and are not followed according to the study protocol, only according to clinical practice.